Septerna, Inc.
SEPN
Get informed when a big investor buys or sells
+ FollowMarket Cap$1.55B
Close$
$-32.93
184.5% downside
Current Fair Value
184.5% downsideOvervalued by 184.5% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $1.55 Billion |
|---|---|
| Enterprise Value | $1.56 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-1.1 |
| Beta | 2.28 |
| Outstanding Shares | 44,758,800 |
Return
| Return on Equity | -9.52% |
|---|---|
| Return on Assets | -6.33% |
| Return on Invested Capital | -13.87% |
Valuation & Multiples
| P/E Ratio | -42.53 |
|---|---|
| PEG | 71.14 |
| Price to Sales | 38.98 |
| Price to Book Ratio | 4.87 |
| Enterprise Value to Revenue | 21.65 |
| Enterprise Value to EBIT | -22.94 |
| Enterprise Value to Net Income | -44 |
| Total Debt to Enterprise | 0.05 |
| Debt to Equity | 0.22 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
May 21, 2026
EPS Estimate
$-0.42
Average shareholder expectationRevenue Estimate
$16.98 M
Average shareholder expectationNext Earnings Call
Expected Date
August 10, 2026
EPS Estimate
$-0.43
Average shareholder expectationRevenue Estimate
$19.22 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | -▼ 100.00% |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 0.33%▼ 101.82% |
|---|---|
| Total Invested | $4.99M▼ 99.55% |
| Investors Holding | 19▼ 106.00% |
ESG Score
No data
About Septerna, Inc.
75 employees
CEO: Dr. Jeffrey T. Finer M.D., Ph.D. Septerna, Inc., a clinical-stage biotechnology company, discovers and develops G protein-coupled receptor (GPCR) oral small molecule products candidates for the treatment of endocrinology, immunology and inflammation, and metabolic disea...